The small transmembrane E5 protein of bovine papillomavirus (BPV) transforms cells by forming a stable complex with and activating the platelet-derived growth factor ␤ receptor (PDGF␤R). The E5/PDGF␤R interaction is thought to involve specific physical contacts between the transmembrane domains of the two proteins. Bovine papillomavirus type 1 (BPV-1) 1 induces fibropapillomas in cattle and can tumorigenically transform cultured rodent fibroblast lines (1, 2). The E5 open reading frame of BPV-1 is primarily responsible for the transforming activity of BPV-1 (3-6). E5 encodes a small, 44-amino acid transmembrane protein that exists as a dimer and localizes mostly to cytoplasmic membranes (7, 8) . The manner by which E5 functions to achieve transformation has been studied rather extensively. Previous studies have shown that the platelet-derived growth factor (PDGF) ␤ receptor (PDGF␤R), a transmembrane receptor tyrosine kinase, is the primary cellular target of the E5 protein. Specifically, the E5 protein forms a complex with and constitutively activates the PDGF␤R (9, 10), and activation of this receptor by E5 is required for E5-mediated transformation (11, 12) . Evidence suggests that the E5 protein binds as a dimer to two PDGF␤R molecules and thereby promotes receptor dimerization, resulting in receptor autophosphorylation and stimulation of its intrinsic kinase activity (13). Once the receptor is tyrosine phosphorylated, key cytoplasmic substrates can bind to the receptor and transmit signaling cascades eventuating in cell proliferation (14) . Activation of the PDGF␤R by the E5 protein occurs independent of the native ligand, PDGFBB (11).
1 induces fibropapillomas in cattle and can tumorigenically transform cultured rodent fibroblast lines (1, 2) . The E5 open reading frame of BPV-1 is primarily responsible for the transforming activity of BPV-1 (3) (4) (5) (6) . E5 encodes a small, 44-amino acid transmembrane protein that exists as a dimer and localizes mostly to cytoplasmic membranes (7, 8) . The manner by which E5 functions to achieve transformation has been studied rather extensively. Previous studies have shown that the platelet-derived growth factor (PDGF) ␤ receptor (PDGF␤R), a transmembrane receptor tyrosine kinase, is the primary cellular target of the E5 protein. Specifically, the E5 protein forms a complex with and constitutively activates the PDGF␤R (9, 10) , and activation of this receptor by E5 is required for E5-mediated transformation (11, 12) . Evidence suggests that the E5 protein binds as a dimer to two PDGF␤R molecules and thereby promotes receptor dimerization, resulting in receptor autophosphorylation and stimulation of its intrinsic kinase activity (13) . Once the receptor is tyrosine phosphorylated, key cytoplasmic substrates can bind to the receptor and transmit signaling cascades eventuating in cell proliferation (14) . Activation of the PDGF␤R by the E5 protein occurs independent of the native ligand, PDGFBB (11) .
There have been several reports that the E5 protein can complex with other cellular transmembrane proteins such as other growth factor receptors (15, 16) , ␣-adaptin (17) , and the 16-kDa subunit of the vacuolar H ϩ -ATPase (18 -20) . However, in many of these studies, an interaction with E5 was demonstrated under conditions of overexpression, which may artificially enhance nonspecific interactions. Indeed, it has been shown that although the E5 protein can interact with several different growth factor receptors under conditions of transient overexpression in COS cells (16) , it can interact only with the PDGF␤R when stably expressed at normal levels (16, 21) . Furthermore, since the ability of E5 to interact with these other proteins does not correlate with its transforming activity, the biological significance of such interactions has not been established. Therefore, the PDGF␤R appears to be the most specific target of the E5 protein, and complex formation with this receptor is clearly related to a biochemical (receptor activation) and biological (cellular transformation) response (9 -12) .
In attempts to characterize the E5-PDGF␤R complex, mutagenic analysis of both proteins has been performed. Initial studies indicated that the E5 protein and the PDGF␤R contact each other via transmembrane domain interactions, suggesting a novel mechanism of activation for this receptor (22) (23) (24) . Subsequent studies identified two potential sites of contact between the transmembrane regions of these two proteins. Specifically, it was shown that Lys 499 at the outer juxtamembrane position and Thr 513 at a central transmembrane position within the receptor were required for stable complex formation with the E5 protein (23) . Interestingly, the analogously positioned Asp 33 and Gln 17 , respectively, in the E5 protein, were found to be necessary for the transforming activity of E5 (25, 26) as well as its ability to form a complex with and activate the PDGF␤R (27) . Replacing Lys 499 in the receptor with Asp, Glu, or Ala hindered an interaction with E5, whereas an Arg substitution was tolerated, suggesting a requirement for a positive charge at this position (23) . Similar studies revealed a requirement for a negative charge at the corresponding juxtamembrane position (Asp 33 ) of the E5 protein (27) (28) (29) . Furthermore, it was shown that only amino acids with side groups capable of hydrogen bond formation could functionally substitute for Gln 17 in E5 and permit an interaction with the PDGF␤R (20) . Thus, it was proposed from these studies that complex formation between the PDGF␤R and the E5 protein involves an electrostatic interaction between Asp 33 of E5 and Lys 499 of PDGF␤R and hydrogen bond formation between Gln 17 of E5 and Thr 513 of the receptor (23, 28 -30) . It was also found that dimerization of E5, which is mediated by two extracellular cysteines, is necessary for transformation and stable complex formation with the PDGF␤R (25, 27) . This implies that dimerization of E5 promotes a conformation suitable for making contacts with the PDGF␤R.
We recently obtained data suggesting that several other amino acids within the PDGF␤R transmembrane domain besides Lys 499 and Thr 513 may be required for a stable interaction with the E5 protein (31) . Here, additional mutagenesis analysis of the PDGF␤R was performed to further identify and characterize the PDGF␤R requirements for this interaction. First, we showed that a minimal segment of the PDGF␤R consisting primarily of the transmembrane domain is capable of forming a complex with the E5 protein. We also provide evidence that Thr 513 is important for the interaction by virtue of its polar nature and its position along the transmembrane ␣-helix. Finally, we identify Ile 506 and Leu 520 as additional receptor transmembrane amino acids that play a role in the interaction. This stands to reason because Ile 506 and Leu 520 are predicted to align with Lys 499 and Thr 513 along the same face of the PDGF␤R transmembrane ␣-helix when in a left-handed coiled coil complex with another transmembrane ␣-helix (23) . Taken together, these data suggest that the PDGF␤R contacts the E5 protein via multiple amino acids aligned along a single ␣-helical interface.
EXPERIMENTAL PROCEDURES

Construction of Truncated and Mutant
Receptors-A doubly truncated receptor construct containing primarily the transmembrane domain of the PDGF␤R was created by ligating the truncated portion of a receptor construct lacking the extracellular domain with that of one lacking the intracellular domain at a common transmembrane site. The first step was to attach the COOH-terminal 13 amino acids of the human PDGF␤R (the epitope recognized by the PDGF receptor-specific antibody used in these studies) to the COOH terminus of the truncated receptor construct lacking most of the intracellular domain, pECTM (gift from C. Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden; Ref. 32) . A double-stranded oligonucleotide linker with the sense sequence, 5Ј-GCCCTGCGCCTCGAGCGGAAGCAGAGGATAGC-TTCCTGTAAGCT-3Ј, encoding this epitope and containing SacI compatible ends (gift from D. DiMaio, Yale University) was inserted inframe into the SacI site located at the stop codon of the receptor open reading frame in pECTM. The resulting construct pECTM-epi was subcloned into the pLXSN retrovirus vector by standard methods, generating pECTM-epi-LXSN. Another truncated receptor construct, TPR (gift from C. Heldin), lacking most of the extracellular domain, was also subcloned into the pLXSN retrovirus vector (11), generating pTPR-LXSN. We exploited the XcmI site located in the transmembrane domain of the human PDGF␤R and the SacII site located in pLXSN, and ligated the XcmI-SacII fragment of pECTM-epi-LXSN to the SacIIXcmI fragment of pTPR-LXSN to generate pTMPR. Sequence analysis confirmed that this TMPR lacks extracellular amino acids 38 -530 and intracellular amino acids 574 -1060, corresponding to the published sequence of the human receptor (33) .
Site-directed mutagenesis was performed using the QuikChange procedure (Stratagene) as described by the manufacturer to introduce single or double amino acid substitutions into the transmembrane domain of the PDGF␤R. For each mutation, complimentary oligonucleotides were designed to contain the appropriate base pair mismatches with respect to the wild type receptor sequence (33, 34) that would achieve the desired mutation(s). In the case of I506A, a SpeI site was established by introduction of a silent mutation concomitantly with the I506A substitution, which allowed for screening of potential mutants by SpeI digestion. Templates included the murine or human (either wild type or mutant) PDGF␤R cDNA cloned into the LXSN retroviral vector, which also contains the G418 resistance gene as a selectable marker. The plasmid DNA products from site-directed mutagenesis were sequenced to confirm the presence of the desired mutations.
Cell Culture-The Phoenix ecotropic retrovirus producer cell line was obtained from the ATCC with permission from Dr. Gary Nolan (Stanford University) and maintained in Dulbecco's minimal essential medium with high glucose supplemented with 10% fetal bovine serum. Ba/F3 murine hematopoetic cells were maintained as previously described (11) in RPMI 1640 medium supplemented with 10% fetal bovine serum, antibiotics, 50 M ␤-mercaptoethanol, and 10% WEHI conditioned medium as a source of IL-3 (RPMI/IL-3).
Production of Retrovirus-The various PDGF␤R constructs, E5, and v-sis were introduced into Ba/F3 cells by retroviral mediated gene transfer. The recombinant retroviral vectors used were the receptor-LXSN constructs described above and E5 or v-sis subcloned into the pBabepuro retroviral vector, which contains the puromycin resistance marker. High titer ecotropic retrovirus was obtained from these retroviral vectors as described previously (35) . Briefly, Phoenix ecotropic cells grown to 70 -80% confluence in 60-mm dishes were transfected with 10 g of plasmid DNA using the calcium phosphate method. The next day the media was replaced, and 24 h later the virus-containing supernatant from each dish was collected and filtered through a 0.45-m syringe filter.
Establishment of Stable Ba/F3 Cell Lines-Retroviral infection of Ba/F3 cells was performed as described previously with some modifications (11) . First, Ba/F3 cells stably expressing E5 or v-sis were established by infecting ϳ5 ϫ 10 6 cells with ϳ1-2 ϫ 10 5 colony forming units of pBabepuro-E5 or pBabepuro-v-sis ecotropic retrovirus in 10 ml of RPMI/IL-3 supplemented with 4 g/ml Polybrene. Cells expressing no viral oncogene were generated in parallel by infection with retrovirus derived from the pBabepuro vector alone. 48 h post-infection, 2 ml of the infected cells was added to 8 ml of selective media (RPMI/IL-3 containing 1 g/ml puromycin (Sigma)). After reaching a density of ϳ10 6 cells/ml, cells were passaged again under selection conditions. Selection was repeated through 2-4 additional passages until 100% of a mockinfected culture died, thus establishing stable cell lines. The resulting cells expressing E5, v-sis, or no viral oncogene (Puro) were then infected with recombinant ecotropic retroviruses containing the various LXSNreceptor constructs as described above. Stable cell lines were generated using selective media containing 1 mg/ml G418 (Gemini) as well as puromycin.
Assay for IL-3-independent Growth-Ba/F3 cells expressing a receptor construct without (Puro) or with E5 or v-sis were grown to an approximate density of 1 ϫ 10 6 cells/ml, washed twice with phosphatebuffered saline, and resuspended in an equal volume of RPMI lacking IL-3 (RPMI/ϪIL-3; RPMI 1640 medium supplemented with only 1% fetal bovine serum, antibiotics, 50 M ␤-mercaptoethanol, and without WEHI conditioned medium). Approximately 5 ϫ 10 5 of these cells were inoculated into 10 ml of RPMI/ϪIL-3, incubated at 37°C, and monitored for growth. Total or viable cells were counted using a hemacytometer at various times after seeding. For experiments testing the murine PDGF␤R, Ba/F3 cells that proliferated at least 20-fold during a 10-day period were considered IL-3-independent. For experiments involving the human PDGF␤R, cells that proliferated at least 10-fold during a 10-day period were considered IL-3-independent. Multiple independently derived cell lines of each genotype were tested to the confirm results.
Immunoprecipitation and Immunoblotting-Ba/F3 cells were lysed by incubation in cold EBC buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% Nonidet P-40) supplemented with 1 mM phenylmethylsulfonyl fluoride, 2 mM sodium orthovanadate, 20 mg/ml leupeptin, and 20 mg/ml aprotinin on ice for 15 min. Lysates were cleared of nuclei and cell debris by centrifugation in a microcentrifuge at 15,000 rpm for 10 min at 4°C and the supernatant extracts were used for immunoprecipitation. To immunoprecipitate the E5 protein and any associated protein, 750 -1100 g of extracted protein was incubated overnight at 4°C with ϳ10 l of a rabbit polyclonal antibody directed against the 16 COOH-terminal amino acids of the E5 protein (gift from D. DiMaio). To immunoprecipitate the wild type and mutant forms of the PDGF␤R, 500 -1200 g of extracted protein was incubated overnight at 4°C with 5-12 l of a rabbit polyclonal antibody directed against the COOHterminal 13 amino acids of the human PDGF␤R (gift from D. DiMaio). Following incubation with primary antibody, extracts were incubated with 60 l of a 1:1 slurry of protein-A-Sepharose CL-4B beads (Amersham Biosciences) in Tris-buffered saline (TBS) containing 10% bovine serum albumin for 60 min at 4°C. Beads were then washed 3-5 times with cold EBC buffer. For the experiments presented in Figs. 3A and 5A, the PDGF␤R was precipitated from cell extracts through affinity purification of glycosylated proteins with wheat germ lectin (WGL)-Sepharose beads (Amersham Biosciences). Approximately 100 l of a 1:1 slurry of WGL beads was incubated with 800 -1000 g of EBC extracts overnight at 4°C and then washed as described above. Protein complexes were dissociated from beads by boiling in 2ϫ Laemmli protein sample buffer.
SDS-PAGE and immunoblot analysis was performed as described previously (23) . Briefly, immunoprecipitates were either electrophoresed on an SDS-7.5% polyacrylamide gel and transferred to nitrocellulose (for PDGF receptor or phosphotyrosine imunoblotting) or electrophoresed on an SDS-15% polyacrylamide gel and transferred to Immobilon (Millipore) (for E5 immunoblotting). Blots were blocked for 2 h in milk buffer (5% nonfat dry milk in TBST (10 mM Tris-HCl, pH 7.4, 167 mM NaCl, 1% Tween 20)), then incubated overnight with either a 1:2000 or 1:1000 dilution of monoclonal anti-phosphotyrosine antibody P-Tyr-100 (Cell Signaling) or 4G10 (Upstate Biotechnology), respectively, or a 1:500 -1:1000 dilution of the anti-PDGF␤R or anti-E5 antiserum described above. Following incubation with primary antibody, immunoblots were washed 5 times, 10 min each, in either TBST buffer for phosphotyrosine and E5 immunoblots or TNET buffer (10 mM TrisHCl, pH 7.4, 50 mM NaCl, 1% Tween 20) for PDGF receptor immunoblots. Each blot was then incubated for 1 h with a 1:5000 dilution of a protein A (Pierce; for PDGF␤R or E5 blots) or goat anti-mouse IgG (Pierce; for anti-phosphotyrosine blots) horseradish peroxidase conjugate, washed as above, and subjected to enhanced chemiluminescence (ECL) detection (Amersham Biosciences) as described by the manufacturer. For the experiment presented in Fig. 7A , after ECL detection of the phosphotyrosine immunoblot, primary and secondary antibodies were removed according to the stripping protocol provided by the manufacturer. In brief, membranes were incubated in stripping buffer (100 mM ␤-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) for 30 min at 60°C. The stripped blot was then washed and subjected to ECL detection to ensure that the stripping process was effective. The membrane was then washed in TBST several times, blocked in 5% milk-TBST, and subjected to anti-PDGF␤R immunoblotting as described above.
RESULTS
Previous work identified two specific amino acids of the PDGF␤R, Lys 499 at the extracellular juxtamembrane position and Thr 513 within the transmembrane domain, that are required for an interaction with the BPV E5 protein (23) . To further elucidate the nature of the E5/PDGF␤R interaction and to determine whether other amino acids in the receptor are required for the interaction, additional mutagenesis analysis of the receptor was performed. Receptor mutants were examined for an interaction with the E5 protein in the mouse hematopoietic Ba/F3 cell line because these cells do not express endogenous PDGF receptors, which might otherwise obscure the analysis of mutant receptors. Furthermore, these cells provide a convenient assay for the functional cooperation of receptor mutants with E5 because they normally depend on IL-3 for survival and proliferation (36) . Co-expression of a growth factor receptor and its cognate ligand in these cells can alleviate this requirement for IL-3 (37) apparently because activation of the receptor by the ligand results in a compensatory proliferative signal. Hence, expression of the PDGF␤R with v-sis, which encodes the viral homologue of PDGF BB (38) , or the BPV E5 protein in these cells allows for IL-3-independent growth (11). Therefore, after co-expressing E5 with various PDGF␤R mutants in Ba/F3 cells, we were able to assess the ability of receptor mutants to form a complex with the E5 protein, to undergo activation by E5, and to cooperate with E5 to induce a proliferative response. The functional integrity of each receptor mutant was ascertained by determining the ligand-induced responsiveness to v-sis.
The Transmembrane Domain of the PDGF␤R Is Sufficient for an Interaction with the E5 Protein-Previous work established that the transmembrane domain of the PDGF␤R is required for complex formation with the E5 protein and implicated that the transmembrane domains of the two proteins may contact each other directly (23, 28, 30) . Here, we asked if the transmembrane domain of the receptor by itself is sufficient to interact with the E5 protein. To address this question we constructed a truncated receptor consisting primarily of the PDGF␤R transmembrane domain with only 6 and 30 amino acids derived from the extracellular and intracellular domains, respectively, and tested its ability to form a stable complex with the E5 protein.
In this truncated receptor construct a segment of the human PDGF␤R containing the juxtamembrane lysine, transmembrane domain, and 17 adjacent cytoplasmic amino acids is linked to the COOH-terminal 13 amino acids, the epitope recognized by the PDGF␤R antiserum used in these studies (Fig.  1A) . A recombinant retrovirus carrying the construct for the truncated receptor was introduced by retroviral infection into Ba/F3 cells expressing either the BPV E5 gene or no exogenous gene. Cells stably expressing the truncated receptor were established after selection for a G418 resistance marker present in the retroviral vector. Cells were first analyzed for expression of the truncated receptor by immunoblot analysis with the PDGF␤R antiserum. As expected, the truncated receptor was expressed as a small protein with an apparent molecular mass of ϳ14.5 kilodaltons (Fig. 2, top, left two lanes) . Similar amounts of the truncated receptor were expressed regardless of whether or not E5 was co-expressed. To assess the ability of the truncated receptor to form a stable complex with the E5 protein, cell extracts were immunoprecipitated with an E5 antiserum, and E5 immunoprecipitates were subjected to immunoblotting for the PDGF␤R. Fig. 2 (top, fourth lane) shows that a significant amount of the truncated receptor could be co-immunoprecipitated with the E5 protein. This co-immunoprecipitation was not because of cross-reactivity of the E5 antibody with the truncated receptor, because no truncated receptor was precipitated in the absence of E5 expression (Fig. 2, top, third  lane) . Thus, co-immunoprecipitation of the truncated receptor with the E5 protein indicated the presence of a stable complex between the two proteins. Others were able to independently reproduce these results using the same truncated receptor construct. 2 Furthermore, complex formation between this truncated receptor and the E5 protein was also observed in human diploid fibroblasts (data not shown). Therefore, these results suggest that the PDGF␤R transmembrane domain is sufficient for an interaction with the E5 protein.
Polar (23) . Whereas K499D and K499E substitution mutants were defective for the interaction, a K499R substitution mutant retained the ability to bind to and be activated by E5, implicating a requirement for a positive charge at this position (23) . To further assess the nature of the requirement at transmembrane position 513, we used site-directed mutagenesis to replace Thr 513 with Ser or Asn, two different polar amino acids, generating receptor mutants T513S and T513N (Fig. 1B) . The T513S substitution also was introduced in the receptor in conjunction with a K499R substitution, creating the double substitution mutant K499R/T513S (Fig. 1B) . Retroviral infection was used to introduce the genes encoding the wild type, T513S, K499R/T513S, or T513N receptor into Ba/F3 cells engineered to express E5, v-sis, or no viral oncogene. Stable cell lines were established and the ability of the receptor constructs to interact with and cooperate with the E5 protein was assessed.
First, we examined the cell lines expressing the T513S and K499R/T513S receptor mutants. PDGF␤R immunoblot analysis (Fig. 3A, lower panel) revealed that the mutant and wild type receptors were expressed at similar levels in the various different cell lines. As is typically observed, two different exogenous PDGF␤R forms were evident, a slower migrating mature form and a faster migrating incompletely processed form. Next, the tyrosine phosphorylation status of these receptor mutants was assessed by phosphotyrosine immunoblot analysis and served as an indication of receptor activation. Briefly, glycoproteins were affinity purified from cell extracts with WGL-Sepharose, subjected to SDS-PAGE, and immunoblotted with an antiphosphotyrosine antibody (Fig. 3A, upper panel) . Because no endogenous tyrosine-phosphorylated glycoproteins similar in size to the PDGF␤R could be detected in Ba/F3 cells infected with the empty vector-containing retrovirus (Fig. 3A, LXSN  lanes) , only the exogenously expressed PDGF␤R, when activated, should be detected by this analysis. The wild type receptor when expressed alone in Ba/F3 cells displayed only minimal tyrosine phosphorylation. As expected and shown previously (11, 23 ) the wild type receptor co-expressed with E5 or v-sis was abundantly tyrosine phosphorylated, indicating that the E5 protein and the normal ligand activate the wild type receptor to a similar extent. Neither the T513S nor the K499R/T513S mutant when expressed alone exhibited significant tyrosine phosphorylation, suggesting that neither the single nor double amino acid substitution(s) resulted in a condition of constitutive receptor activation. Both the T513S and the K499R/T513S mutant receptors were substantially tyrosine-phosphorylated when co-expressed with v-sis, illustrating that the T513S and K499R substitutions do not negatively effect the capacity of the PDGF␤R to respond to ligand. Importantly, both receptor mutants were tyrosine-phosphorylated to the same extent as the wild type receptor when co-expressed with E5. Thus, the T513S mutation alone or in conjunction with the K499R mutation did not inhibit receptor activation by E5. Reproducible results were obtained when the PDGF receptor was isolated from extracts by PDGF␤R immunoprecipitation (data not shown).
The ability of these mutant receptors to physically associate with the E5 protein was determined by a co-immunoprecipitation experiment involving PDGF receptor immunoblot analysis of E5 immunoprecipitates (Fig. 3B) . As shown previously (23) , both mature and precursor forms of the wild type PDGF␤R could be co-precipitated with the E5 protein from extracts of Ba/F3 cells (Fig. 3B, upper panel) . No receptor was detected in E5 immunoprecipitates from cells not expressing E5, thereby excluding the possibility of cross-reactivity of the E5 antiserum with the receptor. Similarly, the T513S and K499R/T513S mutant receptors each could be co-immunoprecipitated with the E5 protein ( Fig. 3B ; data not shown). The amount of each co-precipitated mutant receptor was comparable with that of the wild type receptor. These results suggest that the T513S and K499R/T513S mutant receptors were fully capable of forming a physical complex with the E5 protein.
To examine the functionality of complexes formed between each receptor construct and the E5 protein, we took advantage of the fact that co-expression of the PDGF␤R with E5 or v-sis can functionally replace the IL-3 growth requirement of Ba/F3 cells (11) . Ba/F3 cell lines expressing wild type, T513S, or K499R/T513S with or without E5 or v-sis were seeded into media lacking IL-3, monitored for growth, and counted. A representative graph that shows the cell densities achieved after a 14-day incubation in the absence of IL-3 is depicted in Fig. 3C . As expected, none of these receptors when expressed alone could permit IL-3-independent growth of Ba/F3 cells. As shown previously (11, 23) , the wild type PDGF␤R when expressed with v-sis or with E5, conferred an IL-3-independent growth phenotype, indicating that the wild type PDGF␤R is able to functionally cooperate with either viral oncoprotein in Ba/F3 cells. Both the T513S and K499R/T513S mutant receptors, when expressed with E5 or v-sis, were able to induce IL-3-independent growth to a similar extent as the wild type receptor. Thus, the mutant receptors were not only functionally responsive to ligand, but also exhibited a wild type ability to induce proliferation in response to E5. Taken together, our results indicate that the conservative T513S substitution in the transmembrane domain of the wild type PDGF␤R is tolerable for a physical and functional interaction with the E5 protein.
Next, we examined the effect of the T513N mutation on receptor activity and signaling in response to E5. Tyrosine phosphorylation of the T513N receptor mutant was assessed by phosphotyrosine immunoblotting of PDGF␤R immunoprecipitates (Fig. 4A, upper panel) . When expressed alone, the T513N mutant was only minimally tyrosine phosphorylated, indicating that the T513N mutation did not constitutively activate the receptor. Expression with E5 resulted in abundant tyrosine phosphorylation of the T513N mutant, suggesting that it was perfectly capable of being activated by the E5 protein. Interestingly, the precursor form of the T513N mutant was substantially more tyrosine phosphorylated than the wild type receptor in response to E5. As expected, the T513N mutant, like the wild type receptor, was considerably tyrosine phosphorylated when expressed with v-sis, suggesting that it also could be activated by ligand. The increases in tyrosine phosphorylation observed for this mutant in response to E5 or v-sis were not because of corresponding increases in the level of receptor expressed (Fig.  4A, lower panel) .
To assess the ability of the T513N mutant to induce a proliferative signal in response to E5 or v-sis, an IL-3 independence assay was performed. Ba/F3 cells expressing the T513N mutant, with or without E5 or v-sis, were incubated in the absence of IL-3 and counted 7 days later (Fig. 4B) . Cells expressing the T513N mutant alone lost viability and were unable to proliferate. In contrast, co-expression of the T513N mutant with either E5 or v-sis allowed the cells to proliferate in the absence of IL-3 as efficiently as the wild type receptor with FIG. 3 . Biochemical and functional analysis of the T513S and K499R/T513S receptor mutants. Ba/F3 cells expressing the wild type PDGF␤R (WT), mutant receptor T513S or K499R/T513S, or no receptor (LXSN) in the presence (ϩ) or absence (Ϫ) of E5 or v-sis were established as described under "Experimental Procedures." A, glycosylated proteins were isolated from cell extracts by precipitation with WGL-Sepharose, run on an SDS-7.5% polyacrylamide gel, and transferred to nitrocellulose. Blots were subjected to anti-phosphotyrosine (PY) or anti-PDGF receptor (PR) immunoblotting to detect tyrosine-phosphorylated or total receptor levels, respectively. B, the E5 protein and PDGF␤R-E5 complexes were isolated from cell extracts by immunoprecipitation with an anti-E5 rabbit antiserum. Immune complexes were run on SDS-7. E5 or v-sis. These results suggest that the T513N mutant was fully competent for a functional interaction with the E5 protein. Thus, two different polar amino acids can functionally substitute for Thr 513 in the receptor with respect to a productive interaction with the E5 protein.
Altering the Location of Thr 513 in the Transmembrane Domain of the PDGF␤R Is Inhibitory for an Interaction with the E5
Protein-Based on a predicted ␣-helical structure of the PDGF␤R transmembrane domain, both the transmembrane Thr 513 and the juxtamembrane Lys 499 were proposed to fall on the same helical face (23) (Fig. 9) . A previously constructed human PDGF␤R mutant, in which the transmembrane Thr was replaced with a Leu (23), was used as a template to examine the significance of the positioning of this Thr along the transmembrane ␣-helix. Specifically, we introduced an I514T substitution into this mutant, generating the T513L/I514T double substitution mutant (Fig. 1B) . In this mutant the position of the transmembrane Thr is effectively shifted one residue from its native location to an adjacent helical face with respect to the juxtamembrane Lys (Fig. 9 , compare the position of residues 513 and 514). To determine the effect of the I514T substitution when the Thr is maintained at its native location, this substitution was also introduced into the wild type receptor, generating the I514T mutant (Fig. 1B) . The I514T and T513L/I514T mutants were then assessed for their ability to physically and functionally interact with the E5 protein in Ba/F3 cells.
To determine whether these receptor mutants could be activated by the E5 protein in Ba/F3 cells, phosphotyrosine immunoblotting of WGL precipitates or PDGF␤R immunoprecipitates was performed as shown in Figs. 5A and 6A, upper panels. As shown previously (23) , the wild type human PDGF␤R exhibited substantial tyrosine phosphorylation in response to either v-sis or E5 stimulation. Both the T513L/I514T and I514T mutants displayed a level of receptor tyrosine phosphorylation that was comparable with the wild type receptor when expressed with v-sis (Figs. 5A and 6A, respectively) . This indicates that the amino acid substitutions in these mutants did not inhibit ligand-dependent activation of the receptor. The I514T receptor, when co-expressed with E5, exhibited a level of tyrosine phosphorylation comparable with the wild type receptor co-expressed with E5 (Fig. 6A) . However, when co-expressed with E5, the T513L/I514T mutant displayed no detectable tyrosine phosphorylation, suggesting that the E5 protein was unable to induce activation of this receptor mutant. The inhibition of E5-induced activation of this receptor mutant was not because of decreased receptor expression, as receptor expression levels were similar in the cell lines examined (Fig. 5A,  lower panel) . These data suggest that it is the altered location of the transmembrane Thr in the T513L/I514T mutant rather than the I514T replacement itself that is responsible for abrogating receptor activation in response to the E5 protein.
To determine whether the T513L/I514T mutant could form a stable physical complex with the E5 protein, PDGF␤R immunoblot analysis of E5 immunoprecipitates was performed as shown in Fig. 5B . Both mature and precursor forms of the wild type receptor could be co-precipitated with the E5 protein. In contrast, no co-immunoprecipitation of the T513L/I514T mutant with the E5 protein could be detected. This lack of detectable co-immunoprecipitation was not because of a reduction of E5 expression, because the level of E5 expressed with the mutant receptor was similar to that expressed with the wild type receptor (Fig. 5B, lower panel) . Instead, these results indicate that the T513L/I514T mutant lost the ability to form a stable physical complex with the E5 protein.
To determine the biological activity of the I514T and T513L/ I514T mutants, IL-3 independence assays were performed. Ba/F3 cell lines co-expressing either mutant receptor with or without E5 or v-sis were incubated in media lacking IL-3 and monitored for growth. The graphs illustrated in Figs. 5C and 6B depict cell densities after culturing in the absence of IL-3 for 10 and 13 days, respectively. Ba/F3 cells co-expressing I514T or T513L/I514T with v-sis, like cells expressing the wild type receptor with v-sis, proliferated in the absence of IL-3, suggesting that neither the I514T substitution nor altering the location of the transmembrane Thr residue affects the ability of this receptor to functionally cooperate with ligand. Like the wild type receptor, the I514T mutant, when co-expressed with E5, conferred an IL-3-independent growth phenotype (Fig. 6B) . In contrast, the T513L/I514T receptor mutant when expressed with E5 (Fig. 5C ) was unable to induce IL-3-independent proliferation. Thus, the positional change of the transmembrane Thr in the T513L/I514T mutant, and not the I546T substitution by itself, is inhibitory for functional cooperation with the E5 protein. Taken together, these data demonstrate that the location of the Thr in the transmembrane domain of the PDGF␤R plays a significant role in a productive interaction with the E5 protein. 
Ile 506 in the PDGF␤R Is Required for a Productive Interaction with the E5 Protein-Because the required Lys
499 and Thr 513 are predicted to align along the same face of the PDGF␤R transmembrane ␣-helix, additional amino acids located along this face of the ␣-helix such as Ile at position 506 also may be required for stable protein-protein contacts with the E5 protein. To address this hypothesis, Ile 506 was replaced with an alanine (Ala) and the resulting mutant, I506A (Fig.  1B) , was tested for its ability to interact with the E5 protein in Ba/F3 cells.
First, cell lines expressing the wild type receptor or the I506A mutant receptor with or without E5 or v-sis were analyzed for receptor expression levels and receptor tyrosine phosphorylation (Fig. 7A) . PDGF␤R was immunoprecipitated from cell lysates and subjected to SDS-PAGE followed by PDGF␤R or phosphotyrosine immunoblotting. As shown in Fig. 7A (upper panel) , when expressed with v-sis the I506A mutant receptor exhibited a similar level of tyrosine phosphorylation as the wild type receptor with v-sis, suggesting that the I506A substitution does not effect ligand-induced receptor activation. Once again, when co-expressed with E5, the wild type receptor displayed high levels of tyrosine phosphorylation, indicative of its activation by E5. In stark contrast, the I506A receptor co-expressed with E5 exhibited no detectable tyrosine phosphorylation. This did not reflect a lack of I506A receptor expression, because the levels of the mutant and wild type receptor were comparable in the cell lines tested (Fig. 7A, lower panel) . Therefore, these results indicate that the I506A mutant receptor could not be activated in response to E5.
To determine whether the inability of the I506A receptor mutant to be activated by E5 translates to a defective proliferative response to E5, an IL-3 independence assay was performed. The graph in Fig. 7B depicts the density of cells after a 9-day incubation in the absence of IL-3. Expression of the wild type receptor or the I506A mutant alone was not capable of conferring IL-3-independent growth on Ba/F3 cells. When expressed with v-sis, the I506A mutant receptor was capable of stimulating IL-3-independent proliferation to a similar cell density as the wild type receptor expressed with v-sis, illustrating that the I506A substitution did not alter normal receptor signaling in response to ligand. However, unlike the wild type receptor, the I506A mutant receptor when expressed with E5 was unable to induce proliferation in the absence of IL-3. This indicates that this receptor mutant was unable to interact with the E5 protein in a functionally productive manner. In summary, these data provide evidence that Ile 506 is an additional amino acid within the PDGF␤R transmembrane domain necessary for an optimal and completely productive interaction with the E5 protein.
Leu 520 in the PDGF␤R Is Required for a Fully Productive Interaction with the E5 Protein-Lys
499 , Ile 506 , and Thr 513 , the three PDGF␤R amino acids thus far shown to be required for a productive interaction with the E5 protein, all are predicted to align along a single face of the ␣-helix of the receptor transmembrane domain. This supports the hypothesis that the transmembrane domain of the receptor adopts a structure that enables multiple contacts with the E5 protein along a single face of the ␣-helix. To test this hypothesis further we examined the role of Leu 520 of the receptor in the interaction because it is also predicted to align along this "active" ␣-helical face (Fig. 9) . Site-directed mutagenesis was utilized to replace Leu 520 with either an Ala or an Ile, and the resultant receptor mutants L520A and L520I (Fig. 1B) , respectively, were analyzed for their ability to become activated and induce proliferation in response to E5 in Ba/F3 cells.
Receptor activation was determined by phosphotyrosine immunoblot analysis of PDGF␤R immunoprecipitates from extracts of Ba/F3 cells expressing the wild type PDGF␤R, L520A, or L520I receptor mutants with or without E5 or v-sis. As shown in Fig. 8A , substantial tyrosine phosphorylation was detectable for each receptor when co-expressed with v-sis, but not when expressed alone. This result suggests that these amino acid substitutions at position 520 neither induce a state of constitutive activation nor inhibit receptor activation in response to ligand. When co-expressed with E5 the L520I receptor mutant displayed an abundant level of tyrosine phosphorylation, which appeared even greater than that of the wild type receptor expressed with E5. In addition, the L520A receptor mutant was tyrosine phosphorylated to a similar extent as the wild type receptor in response to E5. (Although tyrosine phosphorylation of the precursor form of this mutant was somewhat diminished.) Any induction of receptor tyrosine phosphorylation that was observed could not be explained by a corresponding increase in total receptor levels (Fig. 8A, lower panel) . Thus, neither the L520A nor the L520I substitution appeared to significantly inhibit the ability of the receptor to be activated by the E5 protein.
To examine the ability of the L520I and L520A mutants to functionally cooperate with E5, an IL-3 independence assay was performed. Stable Ba/F3 cell lines expressing the wild type receptor, L520I, or L520A alone or with E5 or v-sis were incubated in the absence of IL-3 and monitored for growth. Fig. 8B is a representative graph showing cell densities after a 9-day incubation in the absence of IL-3. As expected, cell lines expressing each receptor in the absence of E5 or v-sis remained IL-3 dependent for growth. Ba/F3 cells co-expressing the L520I mutant with E5 proliferated in the absence of IL-3 as well if not better than cells co-expressing the wild type receptor with E5. In contrast, the L520A receptor mutant when expressed with E5 only inefficiently permitted IL-3-independent growth. Although cells of this genotype eventually grew in the absence of IL-3 (data not shown), this growth was substantially delayed (typically by 7 days or more) compared with cells expressing the wild type receptor and E5. Thus, the L520A, but not the L520I, substitution appears to be inhibitory for functionally cooperating with the E5 protein. This was not because of a general inability of the L520A mutant to induce a proliferative signal, as it was able to induce IL-3-independent growth as efficiently as the wild type receptor when expressed with v-sis. This suggests that Leu 520 in the transmembrane domain of the PDGF␤R is important for a fully productive interaction with the E5 protein.
DISCUSSION
The data presented here expands the current understanding of protein-protein interactions between the BPV E5 protein and the PDGF␤R. Previous mutagenesis studies showed that the juxtamembrane Lys 499 and the transmembrane Thr 513 in the PDGF␤R and the analogously positioned Asp 33 and Gln 17 , respectively, in the E5 protein play an integral role in complex formation (23, 27, 28, 30) . Because of the nature of these specific amino acid requirements, it was proposed that the PDGF␤R and the E5 protein make two contacts: 1) an electrostatic interaction between charged residues at the juxtamembrane position; and 2) hydrogen bonding between polar residues at a central transmembrane position. Furthermore, it was speculated that the PDGF␤R contacts the E5 protein via a single transmembrane ␣-helical interface (23) . Our data solidifies this model and suggests that more than two receptor amino acids may be involved in making contacts with the E5 protein along this active face of the transmembrane alpha helix.
We first provide evidence that the transmembrane region of the receptor is sufficient for complex formation with the E5 protein. A dually truncated receptor construct with large portions of the intracellular and extracellular domains deleted was still able to physically complex with the E5 protein. Besides the signal peptide sequence and the transmembrane domain, this truncated receptor is predicted to contain only five extracellular amino acids (residues 1-4 linked to Lys 499 ) as well as 17 juxtamembrane cytoplasmic amino acids linked to the COOHterminal epitope. The 17 juxtamembrane cytoplasmic amino acids are not likely to play a role in the interaction because there are only 3 amino acids in the E5 protein that are predicted to be intracellular and these are not essential for its transforming activity (25) . Also, the COOH-terminal epitope of the receptor is not likely to be involved in the interaction because receptor antibodies raised against this epitope can co-immunoprecipitate E5-PDGF␤R complexes (10) . Thus, we conclude that the receptor transmembrane domain with the juxtamembrane Lys 499 is the minimal contiguous region required for an interaction with the E5 protein.
It was previously suggested that the transmembrane Thr 513 of the PDGF␤R interacts with the required Gln 17 in the transmembrane domain of the E5 protein via hydrogen bonding. In support of this hypothesis, extensive mutagenesis of Gln 17 in E5 revealed that only amino acids capable of hydrogen bond formation (typically polar in nature) could maintain the transforming activity of E5 and permit an interaction with and activation of the PDGF␤R (30) . In this paper we tested the tolerability of replacing Thr 513 with two different polar amino acids, Ser and Asn. We found that Asn as well as Ser could functionally replace Thr at position 513 for a fully productive interaction with the E5 protein. Because the side chain of Asn does not contain a hydroxyl group, these results suggest that it is the overall polar nature of the Thr side chain rather than its hydroxyl group that allows for an interaction with the E5 protein. This is consistent with the hypothesis that Thr 
